Commercial Products
Carteyva® (Relmacabtagene Autoleucel Injection)
Approved by the NMPA for Three Indications
- Adult patients with r/r LBCL after two or more lines of systemic therapy
- Adult patients with r/r follicular lymphoma (FL) in which a relapse occurs within 24 months of second-line or higher systemic treatment(Conditional Approval)
- Adult patients with r/r mantle cell lymphoma (MCL) after two or more lines of systemic therapy including BTKi
Recipient of Three National Regulatory Recognitions
-
National Maior New Drua Innovation Proaram
-
Priority Review Designation
-
Breakthrough Therapy Designation
-
China's First Approved Category 1 CAR-T Therapy
-
The Only Approved CAR-T Therapy with Three Indications
-
Included in the National Commercial Health Insurance Innovative Drug Catalog
Three Therapeutic Areas
Explore the scientific evidence and clinical research results by therapeutic area below.
LBCL
Adult patients with r/r LBCL after two or more lines of systemic therapy
FL
Adult patients with r/r follicular lymphoma (FL) in which a relapse occurs within 24 months of second-line or higher systemic treatment (Conditional Approval)
MCL
Adult patients with r/r mantle cell lymphoma (MCL) after two or more lines of systemic therapy including BTKi
Relma-cel Is Based on the Same CAR Construct as Liso-cel, with Optimized Manufacturing and Infusion Processes
